Unichem Laboratories

The numbers behind the story

Q3 FY 25

Q2 FY 25

Q1 FY 25

Q4 FY 24

March 31, 2024
Annual Secretarial Compliance Certificate 2024
Related Party Transactions for half year ended 31.03.2024
Intimation of Board Meeting
Reconciliation of Share Capital as on March 31, 2024
Closure of Trading Window
Corporate Governance Report as on March 31, 2024
Certificate under Regulation 40(9) & 40 (10) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2024
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2024
Compliance Certificate – Regulation 7(3) as on March 31, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2024
Familiarisation Programmes for the financial year 23-24

March 29, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Directors

March 27, 2024
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Resignation of Senior Managerial Personnel (‘SMP’)

February 13, 2024
The United States Food and Drug Administration (USFDA) conducted inspection at the Company’s Ghaziabad (Uttar Pradesh) formulation facility from February 7, 2024 to February 13, 2024.

January 17, 2024
Intimation about the Issuance of “Letter of Confirmation in lieu of original share certificate(s) lost by Shareholder.

January 11, 2024
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg.

Q3 FY 24

Q2 FY 24

Q1 FY 24

Q4 FY 22

Q3 FY 22

Q2 FY 22

Q1 FY 22

Q4 FY 21

Q3 FY-21

January 8, 2021
ICRA – assigned credit rating for Rs. 146 crs (Reduced from Rs. 150 crs) bank facilities

Q2 FY-21

Q1 FY-21

Q4 FY-20

January 3, 2020
Credit Rating from ICRA
Initial Intimation Letter
Revised Intimation Letter

July 27, 2019
Outcome of 56TH AGM
Proceedings
Voting results and Scrutinizer’s report

Q1 FY-20

Q4 FY-19

Q3 FY-19

Q2 FY-19

September 24, 2018

Credit Rating from ICRA

Q1 FY-19

June 20, 2018

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem’s Abbreviated New Drug Application for generic tadalafil (Cialis®). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.

June 6, 2018

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem’s formulation manufacturing facility at Ghaziabad has received an Establishment Inspection Report (EIR) from USFDA indicating closure of inspection. The inspection was conducted by FDA in April 2018.

Q4 FY-18

January 3, 2018
Notice of BuyBack

Q3 FY-18

Q2 FY-18

Q1 FY-18

April 17, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg & 20mg, which are therapeutically equivalent to Feldene Capsules 10mg & 20mg of Pfizer, Inc. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA). For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg given orally once daily. If desired, the daily dose may be divided. Usually lowest effective dosage for the shortest duration, consistent with individual patient treatment goals is recommended. The product will be commercialized from Unichem’s Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.

Q4 FY-17

March 20, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s Formulation manufacturing facility at Goa was inspected by USFDA from March 14th 2017 to March 20th 2017. There were few observations made, and these in the opinion of the Company are correctable ones in respect to which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

March 8, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

March 6, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.

Q3 FY-17

Q2 FY-17

July 23, 2016

Notice of Board Meeting

Q1 FY-17

April 21, 2016

Notice of Board Meeting

April 19, 2016

Notice of Board Meeting